Modeling the cost-effectiveness of infant vaccination with pneumococcal conjugate vaccines in Germany

Background In 2009, the European Medicines Agency granted approval for two higher-valent pneumococcal conjugate vaccines. This study aims to evaluate the costeffectiveness of universal infant (

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The European journal of health economics 2017-04, Vol.18 (3), p.273-292
Hauptverfasser:	Kuhlmann, Alexander, von der Schulenburg, J.-Matthias Graf
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Age Aged Aged, 80 and over Babies Child Child, Preschool Cost analysis Cost-Benefit Analysis Disease Economic Policy Epidemiology Germany Health Care Management Health Economics Health insurance Humans Immunity, Herd Immunization Infant Infant, Newborn Infants Markov Chains Medicine Medicine & Public Health Meningitis Meningitis - economics Meningitis - prevention & control Middle Aged Models, Statistical Mortality Newborn babies Original Paper Otitis Media - economics Otitis Media - prevention & control Pediatrics Pharmacoeconomics and Health Outcomes Pneumococcal Infections - economics Pneumococcal Infections - prevention & control Pneumococcal Vaccines - administration & dosage Pneumococcal Vaccines - economics Pneumonia Pneumonia - economics Pneumonia - prevention & control Population Public Finance Public Health Quality-Adjusted Life Years Sensitivity analysis Streptococcus infections Studies Surveillance Vaccines Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Background In 2009, the European Medicines Agency granted approval for two higher-valent pneumococcal conjugate vaccines. This study aims to evaluate the costeffectiveness of universal infant (
ISSN:	1618-7598 1618-7601
DOI:	10.1007/s10198-016-0770-9